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Abstract
Background: Depression and diabetes are two highly prevalent and co-occurring health problems. Web-based, diabetes-specific
cognitive behavioral therapy (CBT) depression treatment is effective in diabetes patients, and has the potential to be cost effective
and to have large reach. A remaining question is whether the effectiveness differs between patients with seriously impaired mental
health and patients with less severe mental health problems.
Objective: To test whether the effectiveness of an eight-lesson Web-based, diabetes-specific CBT for depression, with minimal
therapist support, differs in patients with or without diagnosed major depressive disorder (MDD), diagnosed anxiety disorder, or
elevated diabetes-specific emotional distress (DM-distress).
Methods: We used data of 255 patients with diabetes with elevated depression scores, who were recruited via an open access
website for participation in a randomized controlled trial, conducted in 2008–2009, comparing a diabetes-specific, Web-based,
therapist-supported CBT with a 12-week waiting-list control group. We performed secondary analyses on these data to study
whether MDD or anxiety disorder (measured using a telephone-administered diagnostic interview) and elevated DM-distress
(online self-reported) are effect modifiers in the treatment of depressive symptoms (online self-reported) with Web-based
diabetes-specific CBT.
Results: MDD, anxiety disorder, and elevated DM-distress were not significant effect modifiers in the treatment of self-assessed
depressive symptoms with Web-based diabetes-specific CBT.
Conclusions: This Web-based diabetes-specific CBT depression treatment is suitable for use in patients with severe mental
health problems and those with a less severe clinical profile.
ClinicalTrial: International Standard Randomized Controlled Trial Number (ISRCTN): 24874457;
http://www.controlled-trials.com/ISRCTN24874457 (Archived by WebCite at http://www.webcitation.org/63hwdviYr)
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Introduction
With an estimated world prevalence of 285 million people,
diabetes mellitus has reached epidemic levels globally [1].
Affecting 10% to 20% of the adult diabetes patients, depression
is to be regarded as a common comorbid health problem that
negatively affects quality of life and diabetes outcomes, and
increases mortality [2,3]. Treating depression in diabetes is
therefore of great importance.
A recent meta-analysis has shown that depression in diabetes
patients can be effectively treated with various antidepressant
treatments, showing the highest effect sizes for psychological
treatment (Cohen d = –0.58, 95% CI, –0.77 to –0.39), compared
with pharmacologic treatment (Cohen d = –0.47, 95% CI, –0.66
to –0.27) or collaborative care (Cohen d = –0.29, 95% CI, –0.43
to –0.16) [4].
Nevertheless, in a substantial portion of diabetes patients,
comorbid depression remains untreated. Underrepresentation
of complaints, underrecognition of depressive symptoms by
health care providers, and inadequate referral can account for
this [5,6]. Another reason for untreated depression in diabetes
patients is the negative stigma of mental health care among
patients who are treated in physical health care, or that they do
not feel at home in a mental health care setting [7,8]. It has also
been suggested that, since generic and disease-specific emotional
distress are not the same, we need to tailor interventions to the
specific needs of this subgroup of patients [9,10]. A depression
treatment that specifically addresses elevated diabetes-specific
emotional distress (DM-distress) could help overcome this last
barrier to treatment. The VU University Medical Center in
Amsterdam, The Netherlands, has recently developed such a
cognitive behavioral therapy (CBT) depression intervention,
specifically tailored to the needs of diabetes patients by
incorporating diabetes-specific topics, such as coping strategies
for diabetes-specific issues [11].
Providing psychological interventions via the Internet could
help overcome barriers to treatment related to travelling distance
and time—for example, it has the potential to avoid reluctance
to seek therapy among patients who are ashamed of needing
psychological help, and it allows patients to work at home, in
their own pace and familiar environment, while saving them
time, and the burden and cost of travelling. Therefore, an
Internet-administered intervention has the potential to have a
broad reach. Internet-administered therapy can also save
therapists time, thus reducing waiting lists [12]. Providing
psychological interventions via the Internet can be a major
advantage specifically for diabetes patients, since they already
spend much time in (somatic) health care, and severe diabetes
complications can cause physical impairments, causing
difficulties in patients’ mobility. Considering these advantages,
the diabetes-specific depression intervention, called
Diabetergestemd.nl (DbG.nl), was offered via the Internet and
tested in a randomized controlled trial (RCT) [13]. The DbG.nl
intervention was found to be significantly more effective than
a waiting-list control condition [14].
A commonly heard criticism in studies regarding Web-based
CBT depression treatment is that most studies do not
differentiate between elevated symptoms of depression
(subclinical depression) and diagnosed depression in the strict
sense, or major depressive disorder (MDD) [15]. This causes
clinicians to need more convincing evidence that online CBT
can help their patients with subclinical depression, but also those
with MDD, especially since the current guidelines for depression
treatment indicate that patients with subclinical depression
warrant a different treatment (low-intensity psychosocial
interventions, such as guided self-help) from patients with MDD
(high-intensity psychosocial intervention, such as individual
CBT) [16]. In the RCT studying the effectiveness of DbG.nl, a
diagnostic instrument was administered, which enabled us to
make a clear distinction between patients with subclinical
depression and patients with MDD. Examination of potential
differences in effectiveness between both subgroups provides
important information regarding the potential utility of the
intervention from a public health perspective.
The elevated prevalence of anxiety disorders in type 1 and type
2 diabetes in comparison with prevalence rates in the general
population has been demonstrated in a systematic review [17].
Since studies on the prevalence of co-occurring anxiety and
mood disorders in diabetes patients have yielded mixed results
[18], we were interested in exploring the co-occurrence of
anxiety disorders in patients with MDD. Furthermore, the
treatment literature indicates that the combination of MDD and
anxiety disorder is more difficult to treat than MDD alone [19].
Therefore, we aimed to examine the effect modification of
anxiety disorders in our study sample.
An important issue to consider in the context of psychological
interventions for people with diabetes is the role of DM-distress
and the need to accurately differentiate DM-distress from
general emotional distress [20]. Previous reports have
emphasized that diabetes patients with elevated symptoms of
depression are not all necessarily clinically depressed, but rather
may have high levels of diabetes-related distress [21,22]. Our
RCT allowed us to test whether the online diabetes-specific
depression intervention was more or less effective in patients
with baseline elevated DM-distress than in those with lower
levels of DM-distress.
To summarize, we set out to answer the following questions:
does the effectiveness of a Web-based, diabetes-specific CBT
depression intervention differ (1) for patients with or without
MDD, (2) for patients with or without an anxiety disorder, and
(3) for patients with or without elevated DM-distress? We
hypothesized that Web-based, diabetes-specific CBT is more
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effective in diabetes patients with MDD, anxiety disorder, or
elevated DM-distress.
To the best of our knowledge, this is the first study that used
data from an RCT to perform secondary analyses to test effect
modification in subgroups of diabetes patients regarding the
effectiveness of a Web-based, diabetes-specific CBT depression
treatment.
Methods
Participants and Procedure
Patients for an RCT were recruited from July 2008 trough
September 2009. We randomly assigned 255 adult diabetes
patients with elevated depressive symptoms (having a score of
16 or higher on the Center for Epidemiologic Studies Depression
scale [CES-D]) to the Web-based diabetes-specific depression
intervention (n = 125) or a 12-week waiting-list control group
(n = 130) (see Figure 1) [13]. Exclusion criteria were a history
of suicide attempt(s) or current suicidal ideation; bipolar
depression or psychotic disorder; pregnancy; recent loss of a
significant other (<6 months ago); and insufficient Internet
literacy. Patients were recruited via advertisements in various
media and could sign up for participation in the study via an
open access study website. The study was advertised as a study
performed by the VU University Medical Center for testing the
effectiveness of diabetes-specific online depression treatment.
It was mentioned that attending was cost-free and no financial
reward was provided.
Patients could individually sign up for participation in the study
through an open access study website. Written informed consent
was obtained by mail and included information on the study,
permission for anonymous data use, and permission to contact
the patient’s general practitioner and treating diabetes physician
for obtaining data on diabetes. After having signed the informed
consent, patients were invited to fill out the baseline assessment
through a personal online questionnaire, and they received a
telephone-administered diagnostic interview.
Individual randomization by computer was used to assign
participants to either the experimental or control condition, at
an individual level, using a 1:1 allocation ratio. Due to the nature
of the study (waiting-list controlled) it was not possible to blind
patients to treatment allocation. The sample size was calculated
based on the expected difference in the primary outcome
variable (ie, depressive symptoms). Based on a statistical power
of 80%, with an alpha of .05, we required 100 participants in
each group to be able to detect differences with an effect size
of 0.35. The design of the RCT on the effectiveness of the
Web-based diabetes-specific depression intervention has been
described in more detail elsewhere [13]. Data of the RCT were
used to perform secondary analyses on effect modification. All
randomly assigned participants were analyzed. The Medical
Ethics Committee of the VU University Medical Center
approved the study. The results of the RCT have been described
elsewhere [14]. In short, the intervention was effective in
reducing depressive symptoms and diabetes-specific emotional
distress.
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Figure 1. CONSORT study flowchart.
Intervention
Participants assigned to the intervention group individually
attended the online course, based on the principles of CBT. The
intervention DbG.nl (www.diabetergestemd.nl) was developed
by the VU University Medical Center in collaboration with the
Trimbos Institute. DbG.nl was based on the effective Web-based
CBT depression intervention Color Your Life [22], the Internet
version of Lewinsohn’s effective and well-known Coping with
Depression course [23]. DbG.nl follows the same format as
Color Your Life, putting emphasis on the following skills:
relaxation, cognitive restructuring (including worrying), positive
reinforcement, assertiveness, communication skills, and
increasing the number of pleasant activities. In short, the course
consists of eight consecutive weekly lessons, consisting of
psychoeducation and focused on skills such as relaxation,
cognitive restructuring (including worrying), positive
reinforcement, social skills, and increasing the number of
activities that are pleasant to the patient. The course contained
written and spoken information and homework assignments
(see Figure 2 for a screenshot) with one-time incorporated email
feedback for each lesson from a coach (qualified psychologist).
Patients were advised to go through one lesson per week. In
case we did not receive their homework, patients were sent
reminders after 1 week and after 2 weeks. If we received no
reply within 3 weeks, we sent participants an email stating that
we had to assume that they were no longer interested in the
intervention, and we invited them to fill out the
postmeasurement. However, if they were still interested, they
were invited to reenter the course. After the course, patients
were invited to fill out feedback forms, and we interviewed
several patients by telephone.
Patients attended nonanonymously, so having multiple identities
was not possible. Coaches only knew patients’ names, and all
personal data were omitted after the patients’medical data were
obtained from their treating physician (to which the patients
consented) and the participant completed or withdrew from the
course. Coaches were blinded to treatment allocation of
participants.
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Figure 2. Screenshot of a lesson in the web-based diabetes-specific course.
Sample Characteristics
Baseline characteristics of our study sample were self-reported
as part of the online assessment. Previous analyses confirmed
successful randomization: intervention and control groups did
not statistically significantly differ regarding demographic or
clinical characteristics at baseline (all P ≥ .05) [14]. Of those
randomly assigned to the intervention group, 53 (42%)
completed the entire eight-lesson course, 30 (24%) completed
no lesson at all, and 7 (6%) never logged into the course. Other
participants dropped out equally divided during the course.
Outcome Measure
Depressive symptoms were self-assessed online with the Dutch
version of the CES-D. The CES-D is a validated self-report
screening instrument that measures the frequency with which
participants have experienced specific depressive symptoms
within the preceding week. The questionnaire contains 20 items
assessed on a 4-point Likert scale. The total score can range
from 0 to 60, where higher scores indicate more depressive
symptoms. In Dutch samples, a cut-off point of 16 or higher is
generally accepted to indicate clinical depression [24].
Potential Effect Modifiers
Based on our research questions, we selected the following three
potential effect modifiers: MDD (yes/no), anxiety disorder
(yes/no), and high versus low level of DM-distress.
To diagnose MDD and anxiety disorder, the Dutch, we
administered by telephone the computerized version of the
World Health Organization Composite International Diagnostic
Interview (WHO CIDI-auto), a fully structured psychiatric
diagnostic interview that assesses diagnostic criteria of mental
disorders according to the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition. The WHO CIDI-auto is a
computerized version of the WHO CIDI, a qualified substitution
of the face-to-face interview [25]. Since questions and routes
are fully specified, no clinical judgment is required. Interviewers
were masters students in clinical psychology of the VU
University in Amsterdam, trained in the administration of the
WHO CIDI-auto by telephone.
DM-distress was measured using the Dutch-validated Problem
Areas in Diabetes scale (PAID), which was self-assessed online
[26]. We compared the effectiveness of our intervention in
patients with elevated DM-distress (using the cut-off of PAID
≥40) with those without elevated DM-distress (PAID <40).
Statistical Analyses
To test effect modification, the course of depressive symptoms
at baseline, posttreatment, and 1-month follow-up between the
intervention and control groups was compared for each potential
effect modifier. We performed generalized estimating equation
(GEE) analyses using 3-way interaction terms (group × time ×
potential effect modifier) to examine whether having an MDD
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(yes/no) diagnosis, anxiety disorder (yes/no) diagnosis, and
elevated DM-distress (PAID ≥40/<40) were significant effect
modifiers in the treatment effect. All analyses were corrected
for baseline depression scores to gain insight into the relative
degree of change, and for time between baseline measurement
and postmeasurement. Also, all potential effect modifiers were
examined on baseline differences for all of the measured
sociodemographic and clinical variables, and all analyses were
corrected for these differences.
In the RCT data, overall study attrition was 32% at
postassessment and 35% at 1-month follow-up. Since study
attrition was higher in noncompleters of the course at the
1-month follow-up than in completers of the course (63% vs
13%; P < .001), attrition was not completely at random. We
therefore imputed missing data using the state-of-the-art multiple
imputation technique with Stata 10.0 software (StataCorp LP,
College Station, TX, USA). Multiple imputation minimally
alters variance of data and thus provides best estimates of true
data [27]. All further statistical analyses were performed using
complete data, with either Stata 10.0 or SPSS 15.0 software
(IBM Corporation, Somers, NY, USA). All results were based
on intention-to-treat analyses.
Results
Baseline Characteristics
Baseline sociodemographic and clinical characteristics of our
study sample are presented in Table 1, and have been described
in more detail elsewhere [14].
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Table 1. Baseline sociodemographic and clinical characteristics of study sample at baseline
P valueWaiting-list control partici-
pants
(n = 130)
CBTa participants
(n = 125)
All patients
(n = 255)
Characteristics
Sociodemographics
.5151 (12)48 (12)50 (12)Age (years), mean (SD)
.1273 (56)82 (66)155 (60.7)Women, n (%)
.87117 (90)110 (88)227 (89.0)White, n (%)
.66100 (77)99 (79)199 (78.0)Marital state: with partner, n (%)
Education level, n (%)
.443 (3)5 (5)8 (3)No formal qualifications
.4066 (51)70 (56)136 (53.3)High school or lower/middle vocational quali-
fications
.2761 (47)50 (40)111 (43.6)College qualifications or more
Clinical characteristics
.5028 (7)29 (7)28 (7)Depressive symptoms (CES-Db, range 16–60),
mean (SD)
.0538 (19)42 (19)40 (19)Diabetes-specific emotional distress (PAIDc,
range 0–100), mean (SD)
.4375 (58)66 (53)141 (55)Type 2 diabetes, n (%)
.367.3 (1.6)7.4 (1.6)7.4 (1.3)Mean HbA1c leveld, %
Self-reported diabetes complications, n (%)
.2314 (11)11 (9)25 (10)Neuropathy
.696 (5)5 (4)11 (4)Nephropathy
.6913 (10)17 (14)30 (12)Retinopathy
.2412 (9)9 (7)21 (8)Foot ulcer
Diagnosis of depressive disorder (WHO CIDI-auto) e , n (%)
.8975 (58)71 (57)146 (57)MDDf
.6833 (25)29 (23)62 (24)MDD, single episode, mild
.4322 (17)26 (21)48 (19)MDD, single episode, moderate
.5612 (9)9 (7)21 (8)MDD, single episode, severe
1.004 (3)4 (3)8 (3)MDD, recurrent episode, mild
.333 (2)1 (1)4 (2)MDD, recurrent episode, moderate
.541 (1)2 (2)3 (1)MDD, recurrent episode, severe
.6815 (12)13 (10)28 (11)Dysthymic disorder
.3652 (40)43 (34)95 (37)Diagnosis of anxiety disorder, n (%)
.2434 (26)25 (20)59 (23)Generalized anxiety disorder
.9212 (9)12 (9)24 (9)Social phobia
.278 (6)4 (3)12 (5)Panic disorder
.622 (2)3 (2)5 (2)Panic disorder with agoraphobia
.148 (6)3 (2)11 (4)Agoraphobia
.8322 (17)20 (16)42 (16)Specific phobia
.067 (5)15 (12)22 (9)Blood-injection-injury type
.479 (7)6 (5)15 (6)Environment type
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P valueWaiting-list control partici-
pants
(n = 130)
CBTa participants
(n = 125)
All patients
(n = 255)
Characteristics
.694 (3)5 (4)9 (4)Situational type
.125 (4)1 (1)6 (3)Animal type
a Cognitive behavioral therapy.
b Center for Epidemiologic Studies Depression scale.
c Problem Areas In Diabetes scale.
d Glycosylated hemoglobin.
e World Health Organization Composite International Diagnostic Interview.
f Major depressive disorder.
Potential Effect Modifiers
As shown in Table 1, over half of the patients in our study
sample (n = 146, 57.3%) had an MDD diagnosis, of whom the
majority (131/146, 89.7%, had a single episode of MDD, not a
recurrent depression. About half of the patients with an MDD
comorbidly had an anxiety disorder (69/146, 47%) and about
half had comorbid elevated DM-distress (80/146, 55%) (Table
2). Furthermore, of patients with an MDD diagnosis, a higher
percentage had type 2 diabetes (94/164, 64% vs 47/109, 43%,
P < .001) and a lower percentage used antidepressant medication
(7/109, 6% vs 21/146, 14%, P < .001). MDD patients reported
higher baseline symptoms of depression, with a mean (SD)
CES-D of 30 (7) versus 26 (7), P < .001, and higher levels of
DM-distress, mean (SD) PAID 42 (20) versus 37 (17), P = .02.
About a third of the total study sample (n = 95, 37%) had an
anxiety disorder diagnosed. Patients with an anxiety disorder
diagnosis had higher baseline depressive symptoms, with a
mean (SD) CES-D of 31 (8) versus 27 (7), P < .001, and
DM-distress, mean (SD) PAID 48 (18) versus 36 (18), P < .001,
and did not differ significantly on any sociodemographic
variable.
Table 2. Prevalence (%) of diagnosed depression, diagnosed anxiety disorder by elevated and low diabetes-specific emotional distress ( 40 < PAIDa
≥ 40) among the study population (n = 255)
Low diabetes-specific
emotional distress
Elevated diabetes-specific
emotional distress
Study population
(n = 255)
146 (57)MDD b
23 (9)46 (18)69 (27)Anxietyc
43 (17)34 (13)77 (30)No anxiety
109 (43)No MDD
9 (4)17 (7)26 (10)Anxiety
53 (21)30 (12)83 (33)No anxiety
128 (50)127 (50)Total
a Problem Areas In Diabetes scale.
b Major depressive disorder measured with the computerized version of the World Health Organization Composite International Diagnostic Interview
(WHO CIDI-auto).
c Anxiety disorder (WHO CIDI-auto).
Half of our study sample (n = 127, 49.8%) had elevated
DM-distress. The patients with elevated DM-distress were
younger, with a mean (SD) age of 47 (3) versus 53 (12), P <
.001; were likelier to be female (85/127, 67% vs 70/128, 55%,
P = .045); had higher baseline depression scores of mean (SD)
CES-D 31 (7) vs 26 (6), P < .001; and were more likely to have
an anxiety disorder (63/127, 50% vs 32/128, 25%, P < .001)
than those without elevated DM-distress.
Potential Effect Modifiers of the Treatment Effect
GEE analysis showed that having a diagnosis of MDD (P = .49)
was not a significant effect modifier in the treatment effect on
depressive symptoms (Table 3). In other words, we did not find
significant differences in reduction of depressive symptoms for
the intervention group versus control group, for patients with
MDD compared with patients without MDD. This is after
correcting for baseline differences in type of diabetes, use of
antidepressant medication, depressive symptoms, and
DM-distress, and the time between pre- and posttreatment.
J Med Internet Res 2012 | vol. 14 | iss. 1 | e2 | p.8http://www.jmir.org/2012/1/e2/
(page number not for citation purposes)
van Bastelaar et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Intention-to-treat analyses (n = 125/130) of effectiveness of a Web-based diabetes-specific depression therapy on symptoms of depression
as assessed by a CES-Da score, testing effect modification by depression status, anxiety disorder, or high level of diabetes-specific emotional distress,
in a cognitive behavioral therapy (CBT) intervention versus waiting-list (WL) control groupb
P
value
1-month follow-upPost treatmentPretreatment
WLCBTWLCBTWLCBT
.4924 (10)20 (12)24 (9)21 (11)30 (7)30 (7)MDDc,d
20 (8)19 (10)21 (8)18 (9)26 (7)27 (7)No MDD
.7125 (10)22 (11)25 (9)23 (11)31 (8)32 (7)Anxiety disorderd
21 (8)19 (11)21 (8)19 (10)26 (6)27 (7)No anxiety disorder
.9224 (9)21 (12)24 (9)22 (11)31 (8)31 (7)Elevated diabetes-specific emotional distress (PAID ≥40)e
21 (9)18 (10)22 (9)18 (10)26 (6)26 (7)No elevated diabetes-specific emotional distress (PAID >40)e
a Center for Epidemiologic Studies Depression scale.
b Data are given as mean (SD). Statistical tests relied on generalized estimating equation analyses. P values indicate level of significance of effect
modification. All analyses are adjusted for baseline CES-D scores, baseline between-group differences on sociodemographic variables, and differences
in time between pretreatment and posttreatment. Data are uncorrected.
c Major depressive disorder.
d Diagnosed using the computerized version of the World Health Organization Composite International Diagnostic Interview (WHO CIDI-auto).
e Problem Areas In Diabetes scale.
Similarly, GEE analysis revealed that having an anxiety disorder
diagnosis was not a significant effect modifier (P = .71) (Table
3). This is after correcting for baseline differences in depressive
symptoms and DM-distress, and the time between pre- and
posttreatment.
Also, having elevated DM-distress (P = .92), was not a
significant effect modifier in the treatment effect on depressive
symptoms (Table 3), after correcting for age, gender, baseline
depression scores, baseline diagnosis anxiety disorder, and the
time between pre- and posttreatment.
Discussion
In this study, we aimed to answer the following questions: does
the effectiveness of a Web-based diabetes-specific CBT
depression intervention differ (1) for patients with or without
MDD, (2) for patients with or without an anxiety disorder, and
(3) for patients with or without elevated DM-distress? Secondary
analyses from an RCT comparing Web-based diabetes-specific
depression treatment versus a waiting-list control in patients
with type 1 and type 2 diabetes with comorbid depression show
that a diagnosis of MDD or anxiety disorder, or reporting high
DM-distress does not significantly modify the effect of
Web-based diabetes-specific CBT depression treatment. These
findings thus suggest that there is no reason to exclude patients
with more severe depression or anxiety from participating in
what is often considered a first line of treatment for patients
with mild depression, following a stepped-care approach [28].
When referring patients to this Web-based, diabetes-specific
depression treatment, screening for depressive symptoms using
a questionnaire seems advisable, omitting the need to strictly
diagnose MDD. It is at this stage unclear for whom the
intervention is contraindicated. In our study, patients were
excluded in case of psychotic features, suicidal ideation or a
history of suicide attempts, or previous admission to a
psychiatric hospital for depression treatment. It seems advisable,
at minimum, to check for suicidal ideation and psychotic
features as exclusion criteria.
Interestingly, roughly half of the participating diabetes patients
with comorbid depression reported high disease-specific distress,
which was found not to be an effect modifier. This suggests
that DbG.nl is suitable for patients with and without high
diabetes-related distress. In a future study, comparing the
diabetes-specific intervention with a generic Web-based
depression intervention on effectiveness and attractiveness from
the patient’s perspective would be of great importance.
In interpreting the results of our study, we should acknowledge
several strengths and limitations of the study. The most
important strengths are the design of the study, being an RCT,
and the innovative character of the study. This is the first study
that tested the effectiveness of Web-based, diabetes-specific
depression treatment in different subgroups of patients.
Moreover, we administered a diagnostic interview and used
validated instruments for measuring depressive symptoms and
DM-distress.
An important limitation that needs mentioning is that examining
the effect modification was not the primary aim of our RCT.
Therefore, this study was not powered to detect significant
differences in effect between patients with and without MDD,
anxiety disorder, and elevated DM-distress. Yet, due to the
relatively large sample size of the study, we had substantial
subgroups of patients to compare (n = 146 patients with MDD,
n = 109 patients with anxiety disorder, and n = 127 patients
with elevated DM-distress). We were unable to test whether
specifically MDD was more difficult to treat when patients had
comorbid anxiety, but instead examined the effect modification
in the full sample of subclinically depressed and MDD patients.
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Since in our study sample a substantial group had both MDD
and anxiety disorder, this stresses the importance of testing the
effect modification of anxiety disorder in a sample of diabetes
patients with MDD.
Regarding external validity of our results, we should take into
account that our sample consisted largely of white, relatively
well-controlled diabetes patients, including only a few
less-educated people (about 8/255, 3%) and patients older than
65 years (24/255, 9%). Considering the increased prevalence
of diabetes in ethnic populations, older people, and those with
lower social economic status, further research is warranted to
test the effectiveness of our program in more diverse
populations. We also observed that only a few of the participants
with MDD had recurrent depression, even though MDD has
been shown to be more recurrent in diabetes patients [29].
Perhaps the underrepresentation of patients with recurrent
depressive episodes in our study can be explained by these
patients already having tried several forms of depression
treatment and, and therefore being less willing to try a new form
of therapy (Web-based therapy). Future studies should make
an effort to attract diabetes patients with recurrent depression
in order to test the effectiveness of Web-based therapy.
Conclusions
Findings from this study provide the first evidence to suggest
that Web-based diabetes-specific depression treatment is
effective in patients with mild to more severe depression, with
or without comorbid anxiety disorder. Information on
differential effects of Web-based therapy is vital to make
evidence-based recommendations regarding indication, referral,
and reimbursement of the intervention.
The Web-based, diabetes-specific depression treatment seems
to have high usability because it can serve as an intervention
for both subclinical and clinical depression in diabetes patients.
Given its Web-based administration, this diabetes-specific
depression treatment has the potential to reach large patient
populations and to be cost effective.
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